Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + TACE in Unresectable HCC
NCT00335829Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2006
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Yale University. Started May 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00335829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335829.